Your browser doesn't support javascript.
loading
Apremilast is a potentially useful treatment for severe palmoplantar pustulosis with extra-palmoplantar symptoms.
Fukushima-Nomura, Ayano; Takamiyagi, Saeko; Kakuta, Risa; Ito, Yoshihiro; Hirai, Ikuko; Umemoto, Junichi; Hanaoka, Hironari; Kaneko, Yuko; Tanese, Keiji.
Afiliación
  • Fukushima-Nomura A; Department of Dermatology Keio University School of Medicine Tokyo Japan.
  • Takamiyagi S; Department of Dermatology Keio University School of Medicine Tokyo Japan.
  • Kakuta R; Department of Dermatology Keio University School of Medicine Tokyo Japan.
  • Ito Y; Department of Dermatology Keio University School of Medicine Tokyo Japan.
  • Hirai I; Department of Dermatology Keio University School of Medicine Tokyo Japan.
  • Umemoto J; Horinouchi-ekimae Dermatology Clinic Yokohama Japan.
  • Hanaoka H; Department of Rheumatology Keio University School of Medicine Tokyo Japan.
  • Kaneko Y; Department of Rheumatology Keio University School of Medicine Tokyo Japan.
  • Tanese K; Department of Dermatology Keio University School of Medicine Tokyo Japan.
Skin Health Dis ; 4(2): e336, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38577036
ABSTRACT
Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disorder affecting the palms and soles. In rare cases, severe patients develop acute extra-palmoplantar lesions often accompanied by arthralgia. Such cases with extensive symptoms often necessitate systemic treatments with variable efficacy and potential side effects. Apremilast, known for its broad immune response modulation, presents promise as a therapeutic option for severe PPP with joint and extra-palmoplantar lesions. This case highlights apremilast as a potential systemic treatment for such cases with minimal side effects.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Skin Health Dis Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Skin Health Dis Año: 2024 Tipo del documento: Article